Literature DB >> 9032216

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa.

J N Baraniuk1, M Ali, D Brody, J Maniscalco, E Gaumond, T Fitzgerald, G Wong, A Yuta, J C Mak, P J Barnes, R Bascom, T Troost.   

Abstract

Glucocorticoids are hypothesized to induce beta2-adrenergic receptors (beta2-R) and their functions. The ability of dexamethasone (DEX) in vitro and beclomethasone dipropionate (BDP) in vivo to induce beta2-R messenger RNA (mRNA) and function was investigated in human nasal mucosa. In this tissue, albuterol does not stimulate exocytosis either in vivo or in vitro (Mullol and coworkers, 1992). Therefore, induction of beta2-R-mediated glandular exocytosis by glucocorticoids was proposed as an unambiguous outcome measure. Human nasal mucosa was cultured for 3 d with and without 1 microM DEX, then challenged with media or 100 microM albuterol. Culture supernatants were collected for measurement of exocytosed glandular products. Explant mRNA was extracted for reverse transcriptase-polymerase chain reaction (RT-PCR), and in situ hybridization of beta2-R mRNA performed. In vivo, normal subjects received saline or BDP for 3 d before albuterol nasal provocation. Concentrations of exocytosed products were measured in nasal secretions. RNA was extracted from nasal epithelial scrapings for RT-PCR. In vitro, DEX treatment induced albuterol-mediated glandular exocytosis (p < 0.04), and increased the steady-state beta2-R/beta-actin mRNA ratio (p < 0.05), and expression of beta2-R mRNA in glands. In vivo, BDP increased the beta2-R/beta-actin mRNA ratio in epithelial scrapings (p < 0.04), but did not induce albuterol-mediated glandular secretion. We conclude that glucocorticoids increase steady-state beta2-R mRNA levels in vivo and in vitro, and can induce beta2-R function as assessed by submucosal gland exocytosis in vitro. While topical BDP induced epithelial beta2-R mRNA, it did not modulate exocytosis from the deeper submucosal glands.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032216     DOI: 10.1164/ajrccm.155.2.9032216

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

Review 1.  Interactions between corticosteroids and beta2-agonists.

Authors:  Robert J Hancox
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 2.  Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Omar A Minai; Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 3.  Glucocorticosteroids: current and future directions.

Authors:  Peter J Barnes
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 4.  Biochemical basis of asthma therapy.

Authors:  Peter J Barnes
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

Review 5.  Nonrespiratory Comorbidities in Asthma.

Authors:  Juan Carlos Cardet; Adeeb A Bulkhi; Richard F Lockey
Journal:  J Allergy Clin Immunol Pract       Date:  2021-09-04

Review 6.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.

Authors:  Caroline Fenton; Gillian M Keating
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Budesonide/formoterol combination in COPD: a US perspective.

Authors:  Amir Sharafkhaneh; Amarbir S Mattewal; Vinu M Abraham; Goutham Dronavalli; Nicola A Hanania
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-10-05

9.  Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation.

Authors:  D Wyss; O Bonneau; A Trifilieff
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

Review 10.  Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.